TY - JOUR
T1 - Nanomedicine targets iron metabolism for cancer therapy
AU - Lin, Liangru
AU - Chen, Hanqing
AU - Zhao, Ruifang
AU - Zhu, Motao
AU - Nie, Guangjun
N1 - Funding Information:
National Natural Science Foundation of China, Grant/Award Number: 31820103004, 321171370; KC Wong Education Foundation, Grant/Award Number: GJTD-2018-03; Start-up Foundation of NCNST, CAS, Grant/Award Number: NSKF202004, NSKF202007; Research Foundation of Guangzhou First People’s Hospital, Grant/Award Number: KY09040029. This work was supported by the National Natural Science Foundation of China (31820103004 and 321171370), the KC Wong Education Foundation (GJTD-2018-03), the Start-up Foundation of NCNST, CAS (NSKF202004 and NSKF202007), and the Research Foundation of Guangzhou First People’s Hospital (KY09040029).
Funding Information:
This work was supported by the National Natural Science Foundation of China (31820103004 and 321171370), the KC Wong Education Foundation (GJTD‐2018‐03), the Start‐up Foundation of NCNST, CAS (NSKF202004 and NSKF202007), and the Research Foundation of Guangzhou First People’s Hospital (KY09040029).
Funding Information:
National Natural Science Foundation of China, Grant/Award Number: 31820103004, 321171370; KC Wong Education Foundation, Grant/Award Number: GJTD‐2018‐03; Start‐up Foundation of NCNST, CAS, Grant/Award Number: NSKF202004, NSKF202007; Research Foundation of Guangzhou First People’s Hospital, Grant/Award Number: KY09040029.
Publisher Copyright:
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2022/3
Y1 - 2022/3
N2 - Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side-effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron-regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers.
AB - Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side-effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron-regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers.
KW - cancer therapy
KW - ferroptosis
KW - iron metabolism
KW - iron reductive therapy
KW - nanodrug delivery system
KW - Antineoplastic Agents/administration & dosage
KW - Humans
KW - Neoplasms/drug therapy
KW - Combined Modality Therapy
KW - Ferroptosis/drug effects
KW - Drug Delivery Systems
KW - Animals
KW - Iron Overload/drug therapy
KW - Iron/metabolism
KW - Nanomedicine
UR - http://www.scopus.com/inward/record.url?scp=85124559376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124559376&partnerID=8YFLogxK
U2 - 10.1111/cas.15250
DO - 10.1111/cas.15250
M3 - Review article
C2 - 34962017
AN - SCOPUS:85124559376
SN - 1347-9032
VL - 113
SP - 828
EP - 837
JO - Cancer Science
JF - Cancer Science
IS - 3
ER -